GlassScriptPhysician profile
Fadel Shammout
NPI 1124205539
$12,578.97
in general payments reported to CMS, 2019-2025
10 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $60.18 · 2021: $105 · 2022: $113 · 2023: $8,385 · 2024: $3,634 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $10K · Travel and Lodging: $1,758 · Food and Beverage: $543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $10,000.00 |
| Travel and Lodging | $1,758.14 |
| Food and Beverage | $542.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,210.37 | 2022-2025 | Davinci Xi, Da Vinci Surgical System |
| Mimedx Group, INC. | $118.11 | 2025 | |
| Abbvie INC. | $85.02 | 2020-2021 | |
| Glaxosmithkline, LLC. | $56.46 | 2024-2025 | Shingrix |
| Coopersurgical, INC. | $26.55 | 2021-2022 | |
| Evofem Biosciences, INC. | $20.34 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.74 | 2020 | |
| Merck Sharp & Dohme LLC | $17.72 | 2021 | |
| Octapharma USA, INC. | $16.29 | 2025 | Fibryga |
| Organon LLC | $10.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadel Shammout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.